{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:50:10Z","timestamp":1789973410373,"version":"4.0.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1097\/jcp.0b013e3182970490","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T15:27:22Z","timestamp":1371137242000},"page":"472-478","source":"Crossref","is-referenced-by-count":62,"title":["A Randomized Clinical Trial of Histamine 2 Receptor Antagonism in Treatment-Resistant Schizophrenia"],"prefix":"10.1097","volume":"33","author":[{"given":"Katarina","family":"Meskanen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Ekelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarmo","family":"Laitinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pertti J.","family":"Neuvonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Haukka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pertti","family":"Panula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Ekelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1176\/appi.ps.56.6.735","article-title":"Recovery from schizophrenia: a concept in search of research.","volume":"56","author":"Liberman","year":"2005","journal-title":"Psychiatr Serv"},{"key":"R2-4-20210128","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1176\/ajp.145.5.578","article-title":"Deficit and nondeficit forms of schizophrenia: the concept.","volume":"145","author":"Carpenter","year":"1988","journal-title":"Am J Psychiatry"},{"key":"R3-4-20210128","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/syn.20303","article-title":"Psychosis pathways converge via D2 high dopamine receptors.","volume":"60","author":"Seeman","year":"2006","journal-title":"Synapse"},{"key":"R4-4-20210128","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1517\/14728214.2011.556112","article-title":"Emerging drugs for schizophrenia.","volume":"16","author":"Biedermann","year":"2011","journal-title":"Expert Opin Emerg Drugs"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrn1034","article-title":"The role of histamine and the tuberomamillary nucleus in the nervous system.","volume":"4","author":"Haas","year":"2003","journal-title":"Nat Rev Neurosci"},{"key":"R6-4-20210128","first-page":"253","article-title":"International Union of Pharmacology. XIII. Classification of histamine receptors.","volume":"49","author":"Hill","year":"1997","journal-title":"Pharmacol Rev"},{"key":"R7-4-20210128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.euroneuro.2004.10.001","article-title":"Histamine H1 receptors in schizophrenic patients measured by positron emission tomography.","volume":"15","author":"Iwabuchi","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"R8-4-20210128","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0920-9964(94)00034-6","article-title":"Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms.","volume":"14","author":"Prell","year":"1995","journal-title":"Schizophr Res"},{"key":"R9-4-20210128","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0006-3223(91)90290-3","article-title":"Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia.","volume":"30","author":"Nakai","year":"1991","journal-title":"Biol Psychiatry"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0924-977X(01)00121-3","article-title":"Application of genomics to drug design: the example of the histamine H3 receptor.","volume":"11","author":"Schwartz","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"key":"R11-4-20210128","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/mol.62.2.389","article-title":"Behavioral characterization of mice lacking histamine H3 receptors.","volume":"62","author":"Toyota","year":"2002","journal-title":"Mol Pharmacol"},{"key":"R12-4-20210128","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1460-9568.2003.02422.x","article-title":"Ciproxifan, a histamine H3-receptor antagonistinverse agonist, modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum.","volume":"17","author":"Pillot","year":"2003","journal-title":"Eur J Neurosci"},{"key":"R13-4-20210128","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/0140-6736(90)91237-5","article-title":"Effect of famotidine on deficit symptoms of schizophrenia.","volume":"335","author":"Kaminsky","year":"1990","journal-title":"Lancet"},{"key":"R14-4-20210128","first-page":"239","article-title":"An open-label study of famotidine as a treatment for schizophrenia.","volume":"20","author":"Whiteford","year":"1995","journal-title":"J Psychiatry Neurosci"},{"key":"R15-4-20210128","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/00002826-199312000-00005","article-title":"Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data.","volume":"16","author":"Deutsch","year":"1993","journal-title":"Clin Neuropharmacol"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00002826-199619040-00007","article-title":"An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy.","volume":"19","author":"Rosse","year":"1996","journal-title":"Clin Neuropharmacol"},{"key":"R17-4-20210128","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/304065a0","article-title":"Specific binding of 3H-tiotidine to histamine H2 receptors in guinea pig cerebral cortex.","volume":"304","author":"Gajtkowski","year":"1983","journal-title":"Nature"},{"key":"R19-4-20210128","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archpsyc.1982.04290080006002","article-title":"Diagnostic criteria for schizophrenia: reliabilities and agreement between systems.","volume":"39","author":"Endicott","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"R20-4-20210128","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archpsyc.1982.04290070020005","article-title":"Negative symptoms in schizophrenia: definition and reliability.","volume":"39","author":"Andreasen","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"R21-4-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"R23-4-20210128","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2125.1987.tb03261.x","article-title":"CSF concentrations of famotidine.","volume":"24","author":"Kagevi","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"R24-4-20210128","first-page":"1040","article-title":"Carrier-mediated uptake of H2-receptor antagonists by the rat choroid plexus: involvement of rat organic anion transporter 3.","volume":"32","author":"Nagata","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00004836-199810000-00014","article-title":"Central nervous system reactions associated with famotidine: report of five cases.","volume":"27","author":"Odeh","year":"1998","journal-title":"J Clin Gastroenterol"},{"key":"R26-4-20210128","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1248\/bpb.30.1003","article-title":"Pharmacokinetic and pharmacodynamic properties of lafutidine after postprandial oral administration in healthy subjects: comparison with famotidine.","volume":"30","author":"Ikawa","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"R27-4-20210128","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/j.1552-4604.1989.tb03399.x","article-title":"Impaired bioavailability of famotidine given concurrently with a potent antacid.","volume":"29","author":"Barzaghi","year":"1989","journal-title":"J Clin Pharmacol"},{"key":"R28-4-20210128","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2165\/00003088-199121030-00003","article-title":"Clinical pharmacokinetics of famotidine.","volume":"21","author":"Echizen","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"R29-4-20210128","first-page":"61","article-title":"Apparent absence of famotidine-antipsychotic drug interactions in patients with chronic schizophrenia.","volume":"21","author":"Prell","year":"1996","journal-title":"J Psychiatry Neurosci"},{"key":"R32-4-20210128","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"R33-4-20210128","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00213-011-2471-5","article-title":"Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo.","volume":"220","author":"Humbert-Claude","year":"2012","journal-title":"Psychopharmacology"},{"key":"R34-4-20210128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neuroscience.2004.12.017","article-title":"The laminar histamine receptor system in human prefrontal cortex suggests multiple levels of histaminergic regulation.","volume":"132","author":"Jin","year":"2005","journal-title":"Neuroscience"},{"key":"R35-4-20210128","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0896-6273(02)01004-8","article-title":"Cognitive mechanisms of nicotine on visual attention.","volume":"36","author":"Lawrence","year":"2002","journal-title":"Neuron"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e3182970490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:01:46Z","timestamp":1620957706000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201308000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3182970490","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}